← All organizations
Highest phase reached
Phase 4
First clinical trial
Dec 1, 2014Last known activity
Oct 22, 2025
Timeline
2000s
- Jun 1, 2009
Tianjin Cansino Biotechnology Inc— Founded
Drugs by trial phase (32 distinct, 46 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (12 own, 0 via acquisition)
- 23-valent pneumococcal polysaccharide vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- acyw135 mcv
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- tetanus toxoid
- ad5-ncov
- bnt162b2
- bivalent recombinant covid-19 vaccine (adenovirus type 5 vector)
- Monovalent group A meningococcal vaccine
Phase 2 (7 own, 0 via acquisition)
Indications
Recent trials (46)
- NCT07203755Lead sponsorPhase 1Oct 22, 2025
- NCT07017777Lead sponsorPhase 3Oct 15, 2025
- NCT06857370Lead sponsorPhase 3Mar 23, 2025
- NCT06732583Lead sponsorPhase 1Feb 28, 2025
- NCT06700148Lead sponsorPhase 3Dec 30, 2024
- NCT06708286Lead sponsorPhase 2/Phase 3Dec 18, 2024
- NCT06577298Lead sponsorPhase 1/Phase 2Oct 31, 2024
- NCT06621654Lead sponsorPhase 1Oct 31, 2024
- NCT06389513Lead sponsorPhase 4Jun 12, 2024
- NCT06226714Lead sponsorPhase 3Mar 1, 2024
- NCT06123663Lead sponsorPhase 1Dec 31, 2023
- NCT06131554Lead sponsorPhase 3Dec 31, 2023
- NCT06120751Lead sponsorPhase 3Dec 31, 2023
- NCT06101173Lead sponsorPhase 1Dec 30, 2023
- NCT06056050Lead sponsorPhase 1Dec 6, 2023
Details
- Founded
- Tianjin, CN Jun 1, 2009
- Last known activity
- Oct 22, 2025